ONC (BeOne Medicines) Debt-to-Asset : 0.22 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ONC BeOne Medicines Ltd ONC
81 GF Score
Price $365.67
GF Value $383.40
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is BeOne Medicines Debt-to-Asset?

BeOne Medicines ONC +4.23% 81 Debt-to-Asset is 0.22 as of Jun. 2026. GuruFocus rates ONC with a GF Score™ of 81/100 and a GF Value™ of $383.40 (Fairly Valued). The stock has 5 warning signs investors should review.

BeOne Medicines's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $302 Mil. BeOne Medicines's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $1,747 Mil. BeOne Medicines's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2026 was $9,176 Mil. BeOne Medicines's debt to asset for the quarter that ended in Jun. 2026 was 0.22.

BeOne Medicines  (NAS:ONC) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

BeOne Medicines Debt-to-Asset Related Terms

BeOne Medicines Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for BeOne Medicines's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeOne Medicines Debt-to-Asset Chart

BeOne Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.09 0.16 0.18 0.24

BeOne Medicines Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.25 0.24 0.24 0.22

ONC vs RVMD, MRNA, ALNY: Debt-to-Asset Comparison

For the Biotechnology subindustry, BeOne Medicines's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BeOne Medicines Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeOne Medicines's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where BeOne Medicines's Debt-to-Asset falls into.


ONC
81GF Score
BeOne Medicines Ltd ONC
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BeOne Medicines Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

BeOne Medicines's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(134.70557451683 + 1865.1029546302) / 8232.6081119238
=0.24

BeOne Medicines's Debt-to-Asset for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(302.1367442 + 1747.4543570803) / 9175.910931935
=0.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.22 mean?
BeOne Medicines (ONC) has a Debt-to-Asset of 0.22 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on BeOne Medicines and its competitors.
Is BeOne Medicines' Debt-to-Asset too high?
BeOne Medicines' current Debt-to-Asset is 0.22. Overall, BeOne Medicines has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Debt-to-Asset compare to RVMD and MRNA?
BeOne Medicines' Debt-to-Asset of 0.22 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on BeOne Medicines and its competitors. BeOne Medicines's current Debt-to-Asset is 0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (ONC) is currently considered Fairly Valued. The stock's GF Value™ is $383.40, compared to a current price of $365.67 — trading 4.6% below its estimated fair value. The current Debt-to-Asset is 0.22. BeOne Medicines' overall GF Score™ is 81/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For BeOne Medicines (ONC), the current Debt-to-Asset is 0.22 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BeOne Medicines (ONC) Overvalued in 2026?

Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued. The current stock price of $365.67 is trading 4.6% below its estimated GF Value™ of $383.40. GuruFocus considers BeOne Medicines to be Fairly Valued.

Key valuation signals for ONC:

  • Debt-to-Asset: 0.22
  • GF Value™: $383.40 vs. price of $365.67 (4.6% below fair value)
  • GF Score™: 81/100 with 5 warning signs

No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BeOne Medicines Business Description

Address c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
81GF Score

Get the complete analysis for ONC

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$365.67
Price
$383.40
GF Value